Pink Sheet Podcast: US FDA Power Plays, Vaccine EUA Without The Sponsor, RBG’s Impact On Pharma

Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.

Source: Shutterstock

Justice Ginsburg wrote only a few opinions related to pharma cases recently, but still had a significant impact on the industry during her tenure on the Supreme Court.

Pink Sheet Senior Writer Derrick Gingery, Senior Editor Brenda Sandburg and Executive Editor Nielsen Hobbs explore the public fight over the US Food and Drug Administration’s reputation in the coronavirus era, as well as a likely extreme scenario related the agency’s approval or emergency use authorization of a vaccine, and recount the impact on pharma of the late Supreme Court Justice Ruth Bader Ginsburg.

Open Media

More On These Topics From The Pink Sheet

Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate

New York State To Conduct Its Own Review Of COVID-19 Vaccines In Another Blow To FDA’s Reputation

Could A COVID-19 Vaccine Gain EUA Without Sponsor Cooperation?

Hahn Says COVID Vaccine Review Could Take Months As Trump Floats Rejecting New EUA Guidance

Ruth Bader Ginsburg’s Impact On Pharma, From Patents To The First Amendment

What Justice Ginsburg’s Death Means For Pharma